Ocular Anti-VEGF Viral Vector Delivery With Steroid Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet medical need for therapies that specifically address the underlying genetic anomalies causing ocular pathologies such as neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR).
Innovation Solution
Administering a therapeutically effective amount of a recombinant viral vector encoding an anti-hVEGF antigen-binding fragment, combined with a steroid treatment, to the eye, particularly in the suprachoroidal or subretinal space, to treat nAMD and DR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is employed to treat ocular diseases, then specific genetic anomalies can be targeted, but delivery to the retina remains challenging
Solution Approach 1:
The patent uses the suprachoroidal space as an intermediary delivery route, allowing viral vectors to be injected through the sclera and reach the retina without direct retinal penetration. This mediator space simplifies the delivery process while maintaining targeted gene transfer to retinal cells.
2Reliability
If anti-VEGF treatment is administered, then neovascularization is inhibited, but intraocular inflammation may occur
Solution Approach 1:
The patent applies preliminary anti-action by co-administering steroid treatment to prevent intraocular inflammation before it can develop. The steroid component counteracts the inflammatory response that would otherwise be triggered by the anti-VEGF viral vector treatment, allowing the full therapeutic benefit to be realized without harmful side effects.
Data Source
AI summary
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the anti-hVEGF treatment comprises administering a therapeutically effective amount of a recombinant viral vector comprising a nucleotide sequence encoding an anti-hVEGF antigen-binding fragment to an eye of the subject; and the steroid treatment comprises administering a therapeutically effective amount of a steroid to the eye of the subject.